MolDX Program Overview
The MolDX program at Palmetto GBA serves as a specialized initiative focused on molecular testing policy implementation and coverage determination within the healthcare system [1]. Operating as a significant Medicare Administrative Contractor (MAC), Palmetto GBA provides comprehensive healthcare services while maintaining specialized molecular diagnostic oversight [1].
The program is guided by an accomplished leadership team of medical directors and specialists who bring extensive expertise in molecular diagnostics and precision medicine. The core leadership includes:
- Gabriel Alejandro Bien-Willner, MD, PhD, serves as Medical Director of the MolDX program, bringing board certification in Anatomic Pathology and Molecular Genetic Pathology, with both MD and PhD degrees from Baylor College of Medicine [1].
- Angella Charnot-Katsikas, MD, FCAP - Board-certified Clinical Pathologist and Medical Microbiologist
- Magdalena Jurkiewicz, MD, PhD, MPH - Clinical and Molecular Genetic Pathologist
- Megan Landsverk, PhD, MB(ASCP)CM, FACMG - Program Director and Board-certified Molecular Geneticist
- Jacqueline Lekostaj, MD, PhD - Board-certified Anatomic and Clinical Pathologist [1]
The program maintains comprehensive service coverage across multiple healthcare domains, including:
- Medicare and Railroad Medicare administration
- Provider enrollment systems
- Specialized diagnostic services [2]
- Ambulatory Surgical Centers
- Independent Clinical Laboratories
- Diagnostic Testing Facilities
- Intensive Cardiac Rehabilitation
- Mammography Centers [1]
Current Operations and Updates
The MolDX Program maintains active engagement through regular open meetings and technical updates scheduled through October 2024 [1]. Recent developments include focused sessions on biomarker risk stratification testing [2] and policy updates regarding proteomics testing reimbursement [3].
- Updated Technical Assessment Forms (July 2024) [5]
- Comprehensive Technical Assessment FAQs [6]
- Regular policy guidance and updates through a consolidated nightly email system [7]
The program continues to evolve its precision medicine initiatives while maintaining focus on core areas including molecular testing landscape assessment, payer controls implementation, and clinical diagnostic pathway development [1].